EU · Phase III-containing · Hypertrophic cardiomyopathy
EU hypertrophic cardiomyopathy trials: sites, PIs, CROs and competition
Five European HCM centres each contribute to five of six late-stage programs reviewed. The network spans 163 distinct listed European sites and 191 named investigators across 21 countries, with recurring experience across obstructive and non-obstructive HCM studies.
Top 5 sites · 6 late-stage HCM studies
Five centres each contribute to five HCM programs
The leading group spans France, Italy, Germany, Spain and Hungary, showing a concentrated European HCM trial network.
Trial participation describes documented HCM experience, not current recruitment performance or capacity.
Top 5 investigators · 6 late-stage HCM studies
Iacopo Olivotto contributes to five programs
Béla Merkely, Frank Edelmann and Roberto Barriales Villa each contribute to four of the six programs reviewed.
Top 5 CROs · Documented HCM support
Fortrea and ICON each support two programs
Documented responsibilities include monitoring, investigator recruitment, regulatory support, project management, data management and safety reporting.
Counts indicate documented study involvement, not sole-vendor responsibility or CRO quality.
European site footprint · By study
ODYSSEY-HCM and SONATA-HCM built the largest site networks
The largest late-stage programs created substantial pools of HCM-experienced centres across Europe.
Current competition · CTIS recruitment status
Recruiting status is concentrated in two programs
SONATA-HCM carries recruiting status across its European network, while CEDAR-HCM has four sites in EU countries currently marked recruiting.
SONATA-HCM's sponsor reported global randomization complete in July 2026, so CTIS recruiting status may overstate remaining patient competition. CEDAR-HCM is pediatric.
Source: TrialAgents analysis of CTIS trial profiles, sites, investigators, country status and documented third-party organizations. Reviewed 21 September 2026.